Navigation Links
By 2019, the Acute Gout Drug Market Will Triple in Size While the Chronic Gout Drug Market Will Reach $1.83 Billion
Date:12/9/2010

BURLINGTON, Mass., Dec. 9, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that by 2019 the acute gout drug market will triple in size to $117 million and the chronic gout drug market will reach $1.83 billion.

According to the new report entitled Acute and Chronic Gout – New Agents Target Refractory Patients and Tap Market Opportunity, both markets will be driven by new high-priced biologics. In September 2010, Savient Pharmaceuticals' Krystexxa became the newest approved drug for chronic gout. Novartis's Ilaris and Regeneron's Arcalyst are both still in development for acute gout.

"These high-priced agents will be reserved for small segments of the population. Krystexxa will be used predominantly in patients with severe treatment-refractory chronic gout, while Ilaris and Arcalyst will likely be used adjunctively with uricase-lowering treatment for patients who experience severe and frequent acute attacks," said Matthew Scutcher, Ph.D., analyst at Decision Resources. "Nonetheless, these agents are likely to provide healthy returns for the companies involved and will drive significant market growth largely because of their high prices."

About Acute and Chronic Gout – New Agents Target Refractory Patients and Tap Market OpportunityThis new special report from the Spectrum series includes primary research in the form of interviews with primary care physicians/general practitioners and specialists treating gout from across the major markets. Decision Resources' epidemiology analysis and forecasts of diagnosed chronic gout prevalence and the number of acute flares of gout over 2009-2019 are also included in the report.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Through 2019, Increased Generic Erosion of Key Agents Such as Lamictal and Depakote/Depakote ER Will Cause a Precipitous $2.3 Billion Decline in the Bipolar Disorder Drug Market
2. Advanced Life Sciences Applies for FDA Orphan Drug Designation for ALS-886 to Treat Acute Lung Injury
3. Nautilus Neurosciences and Tribute Pharmaceuticals Announce Exclusive Canadian License for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine
4. The Acute Ischemic Stroke Drug Market Will Remain Relatively Flat, Increasing from $460 Million in 2009 to Approximately $610 Million in 2019
5. EUSA Pharma Submits ERWINASE(R) Biologics License Application (BLA) for Treatment of Acute Lymphoblastic Leukemia
6. Cheetah Medicals NICOM(R) System for Noninvasive Hemodynamic Monitoring Found to be an Effective Tool for Identification of Acute Heart Failure in the Emergency Department
7. Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
8. Awarepoint to Present ZigBee-based Wireless Sensor Networks for Use in Acute Care Hospitals and Beyond at Mobile Health Expo Speaker Session
9. Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Womens Health Market
10. Daily Intake of Yakult Is Efficacious in Reducing Incidence of Acute Diarrhea in Young Children
11. Bolder BioTechnology Announces $600,000 Grant from NIH to Study Long-Acting IL-11 Analog in Treating Acute Radiation Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... the ralinepag phase 2 trial.  Ralinepag is an oral, ... the treatment of pulmonary arterial hypertension (PAH). The study ... "This marks an important step in the development of ... our pipeline," said Amit Munshi , Arena,s President ...
(Date:12/7/2016)... Dec. 7, 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) has ... Homecare Federation, At-Home IV Infusion Professional, BioRx, MedPro Rx, and XAS ... services, visit diplomat.is/specialty-infusion .  ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ... "As we continue to build on the ...
(Date:12/7/2016)... , Dec. 7, 2016   Rx Savings Solutions ... and its Public Employees Insurance Agency (PEIA) to ... to their innovative healthcare software, ultimately saving money on their ... and provide its members with access to our software that ... more effective, affordable therapy can be found," says Michael ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... 07, 2016 , ... The Cliff Hart Agencies, a Michigan-based ... Dewitt, Williamston, East Lansing, Ann Arbor, and Farmington Hills, is announcing a regional ... tumor. , Jason Bauer and his family are longtime members of the Williamston ...
(Date:12/7/2016)... ... , ... A. Kevin Spann Insurance, a New York-based firm offering insurance and ... a charity drive to raise funds that will benefit the Marine Corps League. , ... Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin Spann team plans ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal ... For The Holiday Party Season. Save Up To 33% Off Botox® and Juvederm® Products ... providing the Phoenix Valley with Delightful Deals on Botox® and Juvederm® just ...
(Date:12/7/2016)... ... December 07, 2016 , ... Gensuite is ... Awards under the Best New Product Launch category. Gensuite’s entry on their EZ ... , BOC Global Events & Training Group is a professional event and training ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Walking With God: Inspirational ... that will inspire the reader to be aware of God's direction in their lives. ... author, Sanford Smith, retired teacher and active church leader. , Sanford says, ...
Breaking Medicine News(10 mins):